Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors

StatusSuspended
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: Following a comprehensive review and strategic realignment of the company's operations and projects in 2026, the Sponsor made the decision to voluntarily suspend the clinical trial. Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 3 entries
    • Interventions: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 (Biological) to Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 (Biological)
    • Eligibility criteria expanded, about 29 words
    • Secondary endpoints: details revised at 3 of 7 entries
    • Site details revised at 2 of 2 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
This is a single-arm, open-label, Phase I study to evaluate the safety, tolerability, and antitumor activity of TX103 CAR-T cells in subjects with TX103-positive advanced solid tumors. The study also aims to explore the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D) of TX103 CAR-T cell therapy.
Trial Details
NCT Number NCT07231081
Lead Sponsor Tcelltech Inc.
Conditions
(from sponsor)		 Solid Tumors
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov